A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

BACKGROUND: Despite improvement with intensive multi-agent chemotherapy, 2-year progression-free survival (PFS) rates for adults with high-risk Burkitt's lymphoma (BL) remains <55%. PATIENTS AND METHODS: We conducted a phase II trial for newly diagnosed classic BL utilizing liposomal doxorub...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841019/
https://ncbi.nlm.nih.gov/pubmed/24146219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt414
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados